摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[4-[4-(Bis(4-methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-α, α-dimethylphenylacetic Acid | 162096-60-8

中文名称
——
中文别名
——
英文名称
4-[4-[4-(Bis(4-methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-α, α-dimethylphenylacetic Acid
英文别名
4-[4-[4(Bis(4-methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylphenylacetic acid;2-[4-[1-hydroxy-4-[4-[hydroxy-bis(4-methylphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
4-[4-[4-(Bis(4-methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-α, α-dimethylphenylacetic Acid化学式
CAS
162096-60-8
化学式
C34H43NO4
mdl
——
分子量
529.72
InChiKey
LMPCSCOVKHFVKE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    39
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    81
  • 氢给体数:
    3
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    甲醇Methyl 4-[4-[4-(Bis(4-Methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-α, α-dimethylphenylacetate 、 、 sodium hydroxide甲醇盐酸乙酸乙酯乙醚 作用下, 以 为溶剂, 反应 3.0h, 以to provide 1.8 g (34%) of 4-[4-[4-(bis(4-methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylphenylacetic acid的产率得到4-[4-[4-(Bis(4-methylphenyl)hydroxymethyl)-1-piperidinyl]-1-hydroxybutyl]-α, α-dimethylphenylacetic Acid
    参考文献:
    名称:
    Piperidine derivatives and process for their production
    摘要:
    本发明涉及以下式子的几乎纯的哌啶衍生物化合物: 其中, R1是氢或羟基; R2是氢;或者R1和R2结合形成负载R1和R2的碳原子之间的第二个键; R3是—COOH或—COOR4; R4具有1至6个碳原子; A、B和D是它们各自环上的取代基,每个取代基可以不同或相同,它们是氢、卤素、烷基、羟基、烷氧基或其他取代基。 本发明还公开了制备这种几乎纯的哌啶衍生物化合物的方法。
    公开号:
    US20060052610A1
点击查看最新优质反应信息

文献信息

  • [EN] PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION<br/>[FR] DERIVES DE PIPERIDINE ET PROCEDES DE PRODUCTION DE CES DERIVES
    申请人:ALBANY MOLECULAR RESEARCH, INC.
    公开号:WO1995000482A1
    公开(公告)日:1995-01-05
    (EN) The present invention relates to substantially pure piperidine derivative compounds of formulae (I) or (II) wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; R3 is -COOH or -COOR4; R4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.(FR) L'invention se rapporte à des composés dérivés de la pipéridine pratiquement purs, de formules (I) ou (II), dans lesquelles: R1 est hydrogène ou hydroxy; R2 est hydrogène; ou bien R1 et R2 pris ensemble forment une seconde liaison entre les atomes de carbone portant R1 et R2; R3 est -COOH ou -COOR4; R4 a 1 à 6 atomes de carbone; A, B et D sont les substituants de leurs chaînes respectives, chacun pouvant être différent ou identique, et sont hydrogène, halogène, alcoyle, hydroxy, alcoxy, ou d'autres substituants. L'invention se rapporte également au procédé de préparation de tels composés dérivés de la pipéridine sous forme pratiquement pure.
    本发明涉及公式(I)或(II)的实质纯的哌啶生物化合物,其中R1为氢或羟基;R2为氢;或者R1和R2一起形成连接R1和R2所在碳原子的第二个键;R3为-COOH或-COOR4;R4具有1至6个碳原子;A、B和D是它们各自环的取代基,每个取代基可以不同或相同,并且是氢、卤素、烷基、羟基、烷氧基或其他取代基。本发明还公开了制备这种实质纯的哌啶生物化合物的方法。
  • Process for production of piperidine derivatives
    申请人:——
    公开号:US20030171590A1
    公开(公告)日:2003-09-11
    The present invention discloses processes for preparing piperidine derivative compounds of the formulae: 1 wherein n is 0 or 1; R 1 is hydrogen or hydroxy; R 2 is hydrogen; or, when n is 0, R 1 and R 2 taken together form a second bond between the carbon atoms bearing R 1 and R 2 , provided that when n is 1, R 1 and R 2 are each hydrogen; R 3 is —COOH or —COOR 4 ; R 4 is an alkyl or aryl moiety; A, B, and D are the substituents of their rings, each of which may be different or the same, and are selected from the group consisting of hydrogen, halogens, alkyl, hydroxy, alkoxy, and other substituents. One process comprises providing a regioisomer of the following formula: 2 wherein Z is —CG 1 G 2 G 3 , 3 m is an integer from 1 to 6; Q and Y are the same or different and are selected from the group consisting of O, S, and NR 5 ; G 1 , G 2 , and G 3 are the same or different and are selected from the group consisting of OR 8 , SR 8 , and NR 8 R 9 ; X 3 is halogen, OR 15 , SR 15 , NR 15 R 16 , OSO 2 R 15 , or NHSO 2 R 15 ; R 6 and R 7 are the same or different and are selected from the group consisting of hydrogen, an alkyl moiety, an aryl moiety, OR 8 , SR 8 , and NR 8 R 9 ; and R 5 , R 8 , R 9 , R 15 , and R 16 are the same or different and are selected from the group consisting of hydrogen, an alkyl moiety, and an aryl moiety and converting the regioisomer to the piperidine derivative compound with a piperidine compound. Another process for producing piperidine derivative compounds comprises providing an &agr;,&agr;-disubstituted-methylbenzene derivative having the formula: 4 wherein X 1 is a halogen, trialkyl or triaryl tin, trialkyl or triaryl borate, trialkyl silicon, alkylhalo silicon, a substituted sulfonic ester, or substituents useful in organometallic coupling reactions and converting the &agr;,&agr;-disubstituted-methylbenzene derivative to the piperidine derivative compound with a piperidine compound. In yet another process, a 4-(&agr;,&agr;-disubstituted)-toluic acid derivative having the formula: 5 wherein X 2 is a halogen; an alkali metal oxide; a moiety having the formula —OR 10 ; a moiety having the formula —SR 10 ; or an amine; and R 10 is selected from the group consisting of hydrogen, an alkyl moiety, and an aryl moiety is provided and converted to the piperidine derivative compound with a piperidine compound.
    本发明披露了制备以下式的哌啶生物化合物的过程:其中n为0或1;R1为氢或羟基;R2为氢;或者当n为0时,R1和R2在承载R1和R2的碳原子之间形成第二个键,但当n为1时,R1和R2分别为氢;R3为—COOH或—COOR4;R4为烷基或芳基基团;A、B和D为它们的环的取代基,每个取代基可以不同或相同,并且从氢、卤素、烷基、羟基、烷氧基和其他取代基的群中选择。其中一种过程包括提供以下式的区域异构体:其中Z为—CG1G2G3,3m为1到6的整数;Q和Y相同或不同,选自O、S和NR5的群;G1、G2和G3相同或不同,选自OR8、SR8和NR8R9的群;X3为卤素、OR15、SR15、NR15R16、OSO2R15或NHSO2R15;R6和R7相同或不同,选自氢、烷基基团、芳基基团、OR8、SR8和NR8R9;以及R5、R8、R9、R15和R16相同或不同,选自氢、烷基基团和芳基基团,并将区域异构体转化为哌啶生物化合物。另一种制备哌啶生物化合物的方法包括提供具有以下式的α,α-二取代甲基苯衍生物:其中X1为卤素、三烷基或三芳基、三烷基或三芳基硼酸酯、三烷基、烷基卤、取代磺酸酯或有机属偶合反应中有用的取代基,并用哌啶化合物将α,α-二取代甲基苯衍生物转化为哌啶生物化合物。在另一种方法中,提供具有以下式的4-(α,α-二取代)-甲苯酸衍生物:其中X2为卤素;碱金属氧化物;具有式—OR10的基团;具有式—SR10的基团;或者胺;并用哌啶化合物将其转化为哌啶生物化合物。
  • Aromatic ketones
    申请人:Albany Molecular Research, Inc.
    公开号:US05663412A1
    公开(公告)日:1997-09-02
    The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
    本发明涉及以下式的基本纯丁啉衍生物化合物:##STR1## 其中,R.sub.1是氢或羟基;R.sub.2是氢;或R.sub.1和R.sub.2在承载R.sub.1和R.sub.2的碳原子之间形成第二键;R.sub.3是--COOH或--COOR.sub.4;R.sub.4具有1到6个碳原子;A、B和D是它们各自环的取代基,每个取代基可以不同或相同,是氢、卤素、烷基、羟基、烷氧基或其他取代基。还公开了制备这种基本纯的吡啶衍生物化合物的方法。
  • Piperidine derivatives
    申请人:Albany Molecular Research, Inc.
    公开号:US05578610A1
    公开(公告)日:1996-11-26
    The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
    本发明涉及公式为: ##STR1## 的基本纯的吡啶衍生物化合物,其中R.sub.1是氢或羟基; R.sub.2是氢; 或R.sub.1和R.sub.2共同形成连接R.sub.1和R.sub.2的碳原子之间的第二个键; R.sub.3是--COOH或--COOR.sub.4; R.sub.4具有1到6个碳原子; A、B和D是它们各自环的取代基,每个取代基可以不同或相同,包括氢、卤素、烷基、羟基、烷氧基或其他取代基。本发明还公开了制备这种基本纯的吡啶衍生物化合物的方法。
  • Aromatic ketones and processes for their preparation
    申请人:Albany Molecular Research, Inc.
    公开号:US05581011A1
    公开(公告)日:1996-12-03
    The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.2 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
    本发明涉及以下公式的基本纯度吡啶衍生物化合物:##STR1##其中,R.sub.1是氢或羟基;R.sub.2是氢;或R.sub.2和R.sub.2共同形成承载R.sub.1和R.sub.2的碳原子之间的第二个键;R.sub.3是--COOH或--COOR.sub.4;R.sub.4具有1至6个碳原子;A、B和D是它们各自环的取代基,每个取代基可以不同或相同,是氢、卤素、烷基、羟基、烷氧基或其他取代基。还公开了制备这种基本纯度吡啶衍生物化合物的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫